7.56 USD
▲+0.05+0.67%
盘后 7.50 -0.79%
2026-11-20
市值
$53.40M
市盈率
—
EPS
-1.74
股息率
—
52 周区间
6.47 – 11.20
成交量
20.10K
Beta
-0.11
目标价
18.50
52W 低 6.4752W 高 11.20
价格走势
公司简介
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in...